Testing new blood and tissue markers to assess thyroid nodule cancer risk
Studies blood and surgical samples from adults with unclear thyroid nodules to find cancer markers.
Plain-language title generated from the registry record
Registry title: Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features
Key facts
- Where
- Cagliari, ItalySee the site
Where in Italy
- AOU CagliariCagliari, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Cagliari
- Trial code
- NCT05428371
- Record updated
- 23 June 2022
- Original description
Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.Read full original descriptionShow less
A Novel, Multimodal, Machine-learning Grounded Approach to Assess the Oncological Risk of Indeterminate Thyroid Nodules
Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.
Inclusion: Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules).
Exclusion: Patients with concomitant thyroid nodules of Bethesda Class V or Class VI; Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment; Patients with distant metastases.